| Code | CSB-RA019677MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Roledumab, targeting the RHD (Rh blood group D antigen) protein. RHD is a transmembrane protein expressed on the surface of red blood cells and represents the most clinically significant blood group antigen after ABO. The presence or absence of RHD determines Rh-positive or Rh-negative blood type status. RHD incompatibility between mother and fetus can lead to hemolytic disease of the newborn (HDN), a potentially severe condition where maternal anti-D antibodies cross the placenta and destroy fetal red blood cells, resulting in anemia, jaundice, and in severe cases, hydrops fetalis.
Roledumab is a therapeutic monoclonal antibody designed to prevent RhD alloimmunization in RhD-negative individuals exposed to RhD-positive red blood cells. This biosimilar antibody serves as a valuable research tool for investigating RHD antigen-antibody interactions, studying mechanisms of immune tolerance in Rh incompatibility, and exploring novel approaches to prevent or manage alloimmunization. It supports immunohematology research and the development of improved prophylactic strategies for HDN prevention.
There are currently no reviews for this product.